Recent Progress in Nanomaterial-Based Biosensors and Theranostic Nanomedicine for Bladder Cancer
Biosensors · 2023
DOI: 10.3390/bios13010106 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biosensors, 2023. Verfasst von Fan-Xin Song und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The Third Affiliated Hospital of Shenzhen University, Shenzhen University, Shenzhen 518000, China. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Nanostructures, Neoplasms, Photochemotherapy. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 160 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Shenzhen Excellent Science and Technology Innovation Talents Training Project, the Undergraduate Training Program for Innovation and Entrepreneurship, Soochow University.
Abstract (Originalsprache)
Bladder cancer (BCa) is one of the most expensive and common malignancies in the urinary system due to its high progression and recurrence rate. Although there are various methods, including cystoscopy, biopsy, and cytology, that have become the standard diagnosis methods for BCa, their intrinsic invasive and inaccurate properties need to be overcome. The novel urine cancer biomarkers are assisted by nanomaterials-based biosensors, such as field-effect transistors (FETs) with high sensitivity and specificity, which may provide solutions to these problems. In addition, nanomaterials can be applied for the advancement of next-generation optical imaging techniques and the contrast agents of conventional techniques; for example, magnetic resonance imaging (MRI) for the diagnosis of BCa. Regarding BCa therapy, nanocarriers, including mucoadhesive nanoparticles and other polymeric nanoparticles, successfully overcome the disadvantages of conventional intravesical instillation and improve the efficacy and safety of intravesical chemotherapy for BCa. Aside from chemotherapy, nanomedicine-based novel therapies, including photodynamic therapy (PDT), photothermal therapy (PTT), chemodynamic therapy (CDT), sonodynamic therapy (SDT), and combination therapy, have afforded us new ways to provide BC therapy and hope, which can be translated into the clinic. In addition, nanomotors and the nanomaterials-based solid tumor disassociation strategy provide new ideas for future research. Here, the advances in BCa diagnosis and therapy mentioned above are reviewed in this paper.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, The Third Affiliated Hospital of Shenzhen University, Shenzhen University, Shenzhen 518000, China.
- Institute of Functional Nano & Soft Materials (FUNSOM), Soochow University, Suzhou 215123, China.
- College of Nano Science & Technology (CNST), Soochow University, Suzhou 215123, China.
- Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
- Department of Urology, The Affiliated South China Hospital of Shenzhen University, Shenzhen University, Shenzhen 518000, China.
ORCID-Profile: Chenghao Wu
Förderung
- National Natural Science Foundation of China
- Shenzhen Excellent Science and Technology Innovation Talents Training Project
- the Undergraduate Training Program for Innovation and Entrepreneurship, Soochow University
Zitieren
APA
Song, F. X., Xu, X., Ding, H., Yu, L., Huang, H., Hao, J., Wu, C., Liang, R., & Zhang, S. (2023). Recent Progress in Nanomaterial-Based Biosensors and Theranostic Nanomedicine for Bladder Cancer. Biosensors. https://doi.org/10.3390/bios13010106
Vancouver
Song FX, Xu X, Ding H, Yu L, Huang H, Hao J, et al. Recent Progress in Nanomaterial-Based Biosensors and Theranostic Nanomedicine for Bladder Cancer. Biosensors. 2023. doi:10.3390/bios13010106
BibTeX
@article{Song2023,
author = {Song, Fan-Xin and Xu, Xiaojian and Ding, Hengze and Yu, Le and Huang, Haochen and Hao, Jinting and Wu, Chenghao and Liang, Rui and Zhang, Shaohua},
title = {Recent Progress in Nanomaterial-Based Biosensors and Theranostic Nanomedicine for Bladder Cancer},
journal = {Biosensors},
year = {2023},
doi = {10.3390/bios13010106}
}
EUVIMED